The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
HOME > REGULATORY
REGULATORY
- Correct Dosage, Administration for Lamictal Asked: Pharmaceuticals Safety Info
January 26, 2012
- Companies Should Be Required to File Notifications for Package Inserts: Subcommittee
January 26, 2012
- HSC Subcommittee Approves Revised Ethical GL for Genomics Research
January 26, 2012
- PMDA Considering Review Procedure Policy for IVD Agents Based on FDA Guidance Draft
January 25, 2012
- 16 APIs Including Aricept, Lyrica to Be Re-Priced for Market Expansion
January 25, 2012
- MHLW to Issue Revised Notifications in Preparation for Application to PIC/S
January 25, 2012
- Revised Basic Plan Against Cancer to Include Pediatric Cancer Measures
January 24, 2012
- Senior Vice Minister Tsuji to Actively Support Creation of 3rd-Party Organization
January 23, 2012
- Proposed Amendment of PAL Would Require Submission of Package Inserts: Mr Kikura
January 23, 2012
- Huge Drop in Compliance Rate for “Explanations in Writing” in Sales of Class 1 OTC Drugs: MHLW Undercover Survey
January 20, 2012
- PMDA to Introduce Direct ADR Reporting System for Patients on Trial Basis
January 20, 2012
- Prof. Nakamura of Keio Univ. Sees Orphan Drug Development Strategy as Reason for Revised Re-pricing Policy
January 20, 2012
- EMA Initiates Review of Oral MS Treatment Gilenya Following Reports of Heart Problems
January 20, 2012
- PAFSC’s Second Committee on Drugs to Review Kyowa Kirin’s ATL Treatment on February 1
January 19, 2012
- PMDA to Expand PGx, Biomarker Consultation System
January 19, 2012
- MHLW Considering “Partial Introduction” of Medico-Economic Evaluation in FY2014
January 18, 2012
- No Serious Concerns Observed for 4 Vaccines: MHLW Study Groups
January 17, 2012
- US Industry Opinion Divided on Japan’s Participation in TPP Talks
January 17, 2012
- PAFSC’s First Committee on Drugs to Review Zyprexa for Depression in Bipolar Disorder on January 27
January 16, 2012
- MHLW Proposes New Fee for Medical Management of Treatment-Resistant Schizophrenia
January 16, 2012
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…